ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: FR-OR040

Phosphate Lowering to Treat Vascular Dysfunction in CKD

Session Information

Category: Bone and Mineral Metabolism

  • 402 Bone and Mineral Metabolism: Clinical

Authors

  • Jovanovich, Anna Jeanette, Denver VA / University of Colorado, Denver, Colorado, United States
  • You, Zhiying, UC Denver, Aurora, Colorado, United States
  • Struemph, Taylor, University of Colorado, Denver, Aurora, Colorado, United States
  • Farmer, Beverly, University of Colorado , Aurora, Colorado, United States
  • Malaczewski, Mikaela R., No, Aurora, Colorado, United States
  • Levi, Moshe, Georgetown University, Washington, District of Columbia, United States
  • Schwartz, Gregory G., Rocky Mtn Regional VA Med Ctr and University of Colorado School of Medicine, Aurora, Colorado, United States
  • Nowak, Kristen L., University of Colorado Denver: Anschutz Medical Campus, Aurora, Colorado, United States
  • Chonchol, Michel, University of Colorado , Aurora, Colorado, United States
Background

Individuals with CKD exhibit vascular endothelial dysfunction and arterial stiffness, independent predictors of cardiovascular disease (CVD) events. Elevated serum phosphorus, even within the normal range, is associated with CVD and mortality in CKD. An acute increase in serum phosphorus impairs endothelial function and increases vascular oxidative stress. We hypothesized that lowering serum phosphorus would improve vascular function and endothelial markers of oxidative stress in CKD.

Methods

We randomized 52 participants with CKD 3b-4 and serum phosphorus within normal limits to receive 12 weeks of lanthanum carbonate or placebo. Primary endpoints were change in brachial artery flow-mediated dilation (FMDBA) and aortic pulse-wave velocity (aPWV). Secondary endpoints were change in FMDBAand aPWV after ascorbic acid infusion and vascular endothelial cell protein expression of NADPH oxidase and NFκB.

Results

Mean age was 65±8 years and mean eGFR was 38±14 mL/min/1.73m2. Baseline serum phosphorus (3.44±0.47 mg/dL) in the lanthanum carbonate group did not change after 12 weeks (p=0.94) while serum phosphorus increased (3.42±0.80 mg/dL to 3.74±1.26 mg/dL; p = 0.09) after 12 weeks in the placebo group. Randomization to lanthanum carbonate did not improve FMDBAor aPWV compared to placebo: lanthanum carbonate baseline FMDBA 3.13%±2.87% and 12-week FMDBA 2.73%±2.48% vs. placebo baseline FMDBA 3.74%±2.86% and 12-week FMDBA 3.09%±2.49%; p=0.52; and lanthanum carbonate baseline aPWV 1214±394 cm/sec and 12-week aPWV 1216±322 cm/sec vs. placebo baseline aPWV 993±289 cm/sec and 12-week aPWV 977±254 cm/sec; p=0.66. Supraphysiologic infusion of ascorbic acid to inhibit superoxide production did not differentially change FMDBA or aPWV between groups at the end of the study (p>0.1 for all). Vascular endothelial cell protein expression of NADPH oxidase and NFκB did not change in either group (p>0.6 for all groups).

Conclusion

Compared to placebo, lanthanum carbonate did not improve vascular endothelial function or stiffness nor did it change endothelial markers of oxidative stress among participants with CKD 3b-4. Infusion of ascorbic acid to inhibit oxidative stress did not differentially affect FMDBA or aPWV.

Funding

  • Veterans Affairs Support